

Special Issue

A Selection of Papers from the Meeting on Cancer Science and Targeted Therapy Conference

Message from the Guest Editors

This Special Issue of *Cancers* will consist of selected papers from the Meeting on Cancer Science and Targeted Therapy Conference (<https://www.cancertherapyconference.com/>) taking place in Melbourne (Australia), on 23–25 March 2020. Although cancer still poses a formidable challenge to clinicians and researchers, recent advances in omics, single-cell analyses, and computational biology are closing the gap towards reaching the goal of developing therapies tailored to single-patient needs. Furthermore, major discoveries in the field of cancer immunotherapy and its combination with molecularly targeted approaches have led to the optimistic view that more effective treatments for the most challenging solid tumors, such as lung, pancreatic, and brain cancers, will be eventually available. We, therefore, invite national and international eminent researchers to discuss basic research, translational research, and clinical trials.

Guest Editors

Prof. Dr. Marco Falasca

Department of Medicine and Surgery, University of Parma, Via Volturno, 39, 43125 Parma, Italy

Prof. Dr. Arturo Sala

Department of Life Sciences, Brunel University London, London UB8 3PH, UK

Deadline for manuscript submissions

closed (31 March 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/36786

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)